IRVINE, Calif., Nov. 5 Masimo (Nasdaq: MASI),the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusionpulse oximetry, announced a new SofTouch(TM) disposable pulse oximetry sensordeveloped specifically for the fragile skin and size of extremely low birthweight (ELBW) infants (<500 grams-1,000 grams) in conjunction with theNeonatology 2008 conference in Miami, Florida. The new LNCS(R) SofTouchNeoPt-500 sensor is exclusively designed to fit ELBW babies and featuresspecial soft foam and non-adhesive attachments to prevent injury to even themost sensitive skin of premature infants.
Barbara Haley, CRTT, NICU Clinical Coordinator, Respiratory Care Servicesat California Pacific Medical Center in San Francisco, CA, stated; "We lovethe LNCS SofTouch NeoPt-500 for the improvement in care it facilitates. It issmaller than other neonatal sensors -- making it a near-perfect fit even forour smallest preemies -- and it is much softer on the skin to maintain skinintegrity. We've also found that the NeoPt-500 makes nurses more efficientbecause the wrap is so much easier to apply and secure."
LNCS SofTouch NeoPt-500 is the first non-adhesive pulse oximetry sensormade specifically for the needs of newborns weighing down to 500 grams orless. At just 20 mm in size, the NeoPt-500 has dimensions that are smallerthan typical neonatal sensors. This means that the distance between theemitter and detector on the NeoPt-500 is much smaller -- enabling the sensorto fit better and more securely on the tiniest hand or foot.
Mitchell Goldstein, M.D., Associate Professor, Pediatrics at Loma LindaUniversity Children's Hospital in Loma Linda, CA, stated; "The new LNCS(R)SofTouch NeoPt-500 sensor solves the problems associated with typical pulseoximetry sensors in ELBW infants. ELBW neonates are much more susceptible toskin burn injury and full thickness ulcer formations caused by improper sensordesign and placement. Skin injury compromises the body's most basic protectionmechanism and, in this most vulnerable population, the problems and risksassociated with sensors not designed or intended for ELBW newborns have muchgreater consequences. Masimo is a unique company that not only understandsthis, but designs and develops clinically-relevant solutions to overcome thesechallenges."
Masimo SofTouch sensors are designed for single-patient use whenever skinsensitivity is a concern. SofTouch sensors incorporate a hook and loop wrap-- allowing the sensor to be quickly and securely applied on wet and slipperysites, and easily repositioned if necessary. Newborn skin is furtherprotected by soft foam material that surrounds the sensor attachment formaximum comfort, and the NeoPt-500 contains no adhesive materials exposed toskin contact areas. This prevents epidermal stripping and skin traumatypically caused by applying and repositioning an adhesive sensor.
Joe E. Kiani, Founder and CEO of Masimo, stated; "The new LNCS SofTouchNeoPt-500 sensor underscores our core philosophy of 'doing what is best forpatient care.' We believe that every patient deserves appropriate monitoringsolutions. That's why Masimo provides over 100 different sensors, eachuniquely designed to deliver the performance and measurement clinicians want-- including 15 different sensor options to address the challenging needs andspecific requirements of neonatal patients."
Masimo (NASDAQ: MASI) develops innovative monitoring technologies thatsignificantly improve patient care -- helping solve "unsolvable" problems. In1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulseoximetry, known as Masimo SET, which virtually eliminated false alarms andincreased pulse oximetry's ability to detect life-threatening events. Morethan 100 independent and objective studies demonstrate Masimo SET provides themost reliable SpO2 and pulse rate measurements even under the most challengingclinical conditions, including patient motion and low peripheral perfusion.In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, abreakthrough noninvasive blood constituent monitoring platform that canmeasure many blood constituents that previously required invasive procedures.Masimo Rainbow SET continuously and noninvasively measures total hemoglobin(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),pulse rate (PR), and perfusion index (PI), allowing early detection andtreatment of potentially life-threatening conditions. Founded in 1989, Masimohas the mission of "Improving Patient Outcomes and Reducing Cost of Care byTaking Noninvasive Monitoring to New Sites and Applications." Additionalinformation about Masimo and its products may be found athttp://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined inSection 27A of the Securities Act of 1933 and Section 21E of the SecuritiesExchange Act of 1934, in connection with the Private Securities LitigationReform Act of 1995. These forward-looking statements are based on currentexpectations about future events affecting us and are subject to risks anduncertainties, all of which are difficult to predict and many of which arebeyond our control and could cause our actual results to differ materially andadversely from those expressed in our forward-looking statements as a resultof various risk factors, including, but not limited to: risks related to ourassumption that the addition of the LNCS(R) NeoPt-500 SofTouch(TM)(R) sensorwill outperform other neonatal pulse oximetry sensors and will serve toincrease clinical accuracy and efficiency and the adoption of Masimotechnology, or serve to substantially increase sensor sales, as well as otherfactors discussed in the "Risk Factors" section of our Quarterly Report onForm 10-Q for the fiscal quarter ended September 27, 2008, filed with theSecurities and Exchange Commission ("SEC") on October 29, 2008, which may beobtained for free at the SEC's website at http://www.sec.gov. Although webelieve that the expectations reflected in our forward-looking statements arereasonable, we do not know whether our expectations will prove correct. Allforward-looking statements included in this press release are expresslyqualified in their entirety by the foregoing cautionary statements. You arecautioned not to place undue reliance on these forward-looking statements,which speak only as of today's date. We do not undertake any obligation toupdate, amend or clarify these forward-looking statements or the "RiskFactors" contained in our Quarterly Report on Form 10-Q for the fiscal quarterended September 27, 2008, whether as a result of new information, futureevents or otherwise, except as may be required under the applicable securitieslaws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and ReducingCost of Care by Taking Noninvasive Monitoring to New Sites and Applications,Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registeredtrademarks of Masimo Corporation.Contact: Dana Banks Masimo Corporation 949-297-7348